Recent blog posts
ELAHERE® Demonstrates Advantage in Overall and Progression-Free Survival in Ovarian Cancer
Latest Hotspot
4 min read
ELAHERE® Demonstrates Advantage in Overall and Progression-Free Survival in Ovarian Cancer
9 October 2023
ImmunoGen Inc. shared outcomes from two assessments of the MIRASOL Phase 3 trial. The trial evaluated safety and effectiveness of ELAHERE® in platinum-resistant ovarian cancer patients positive for the folate receptor alpha, versus chemotherapy.
Read →
MARIPOSA Phase 3 study hits key target, showing improved effectiveness of RYBREVANT® and Lazertinib versus Osimertinib for EGFR-Mut patients
Latest Hotspot
3 min read
MARIPOSA Phase 3 study hits key target, showing improved effectiveness of RYBREVANT® and Lazertinib versus Osimertinib for EGFR-Mut patients
9 October 2023
Landmark Phase 3 MARIPOSA Study achieves its main goal, demonstrating clinically relevant enhancement for RYBREVANT® and Lazertinib when compared to Osimertinib in EGFR-Mut patients.
Read →
Gracell Biotechnologies Announces Clinical Results for FasTCAR-T GC012F in High-Risk, Multiple Myeloma
Latest Hotspot
3 min read
Gracell Biotechnologies Announces Clinical Results for FasTCAR-T GC012F in High-Risk, Multiple Myeloma
9 October 2023
Gracell Biotechnologies has showcased updated long-term data from a continuing Phase 1 trial. This trial is assessing GC012F, a candidate for autologous CAR-T treatment that simultaneously targets CD19 and the B-cell maturation antigen (BCMA).
Read →
Elicio Therapeutics Showcases Findings from the initial Phase of the ELI-002 Study
Latest Hotspot
3 min read
Elicio Therapeutics Showcases Findings from the initial Phase of the ELI-002 Study
9 October 2023
Elicio Therapeutics has revealed encouraging initial data related to relapse-free survival from their ongoing Phase 1 investigation of their primary asset, ELI-002.
Read →
Harpoon Therapeutics Unveils Initial Phase 1 Results of HPN217 at IMS Yearly Conference
Latest Hotspot
3 min read
Harpoon Therapeutics Unveils Initial Phase 1 Results of HPN217 at IMS Yearly Conference
8 October 2023
Harpoon Therapeutics, Inc. has shared the interim outcomes of its Phase 1 clinical trial on the effect of single-agent HPN217 in treating relapsed or refractory multiple myeloma, focused on target dose groups from 2.15 to 12mg.
Read →
Akeso announced FDA's approval of their IND for AK117/Azacitidine combo treatment for Myelodysplastic Syndromes
Latest Hotspot
3 min read
Akeso announced FDA's approval of their IND for AK117/Azacitidine combo treatment for Myelodysplastic Syndromes
8 October 2023
Akeso revealed that the FDA has approved their IND for CD47 Monoclonal Antibody (AK117) combined with Azacitidine for treating Myelodysplastic Syndromes.
Read →
Adcentrx Therapeutics starts Phase 1a/b trials of ADRX-0706, a new ADC targeting Nectin-4, for advanced solid tumors
Latest Hotspot
3 min read
Adcentrx Therapeutics starts Phase 1a/b trials of ADRX-0706, a new ADC targeting Nectin-4, for advanced solid tumors
8 October 2023
Adcentrx Therapeutics reports the initial dosing of a patient in the Phase 1a/b trial of ADRX-0706, an innovative ADC targeting Nectin-4, aimed to treat advanced solid tumors.
Read →
Kallyope progresses to Phase 2, pioneering an oral treatment strategy for both obesity and Type 2 Diabetes
Latest Hotspot
3 min read
Kallyope progresses to Phase 2, pioneering an oral treatment strategy for both obesity and Type 2 Diabetes
8 October 2023
Kallyope, Inc. has commenced its Phase 2 experiment to assess K-757 and K-833.
Read →
New research shows Longhorn Vaccines and Diagnostics' Universal Flu Vaccine, LHNVD-105, triggers strong, durable immunity in lab animals
Latest Hotspot
3 min read
New research shows Longhorn Vaccines and Diagnostics' Universal Flu Vaccine, LHNVD-105, triggers strong, durable immunity in lab animals
8 October 2023
A new research indicates that Longhorn Vaccines and Diagnostics' Universal Flu Vaccine, LHNVD-105, elicits robust and long-lasting immunity in lab animals.
Read →
U.S. FDA Approves Takeda's ENTYVIO (vedolizumab) for continued treatment of severe active Ulcerative Colitis via under-the-skin injection
Latest Hotspot
3 min read
U.S. FDA Approves Takeda's ENTYVIO (vedolizumab) for continued treatment of severe active Ulcerative Colitis via under-the-skin injection
8 October 2023
Takeda announced U.S. FDA approval for ENTYVIO®(vedolizumab) subcutaneous delivery as a maintenance treatment for moderate to severe ulcerative colitis in adults, after initial intravenous therapy.
Read →
Initial Recipient of Omisirge™ (omidubicel-onlv) by Gamida Cell Administered to First Patient
Latest Hotspot
3 min read
Initial Recipient of Omisirge™ (omidubicel-onlv) by Gamida Cell Administered to First Patient
8 October 2023
Gamida Cell Ltd. has declared that the initial patient has been subjected to a stem cell transplantation procedure using Omisirge (omidubicel-onlv).
Read →
Abeona Therapeutics has requested a U.S. FDA Biologics License for expedited review of EB-101, a treatment for Recessive Dystrophic Epidermolysis Bullosa patients
Latest Hotspot
4 min read
Abeona Therapeutics has requested a U.S. FDA Biologics License for expedited review of EB-101, a treatment for Recessive Dystrophic Epidermolysis Bullosa patients
8 October 2023
Abeona Therapeutics Inc. has reported that they've lodged a BLA with U.S. FDA with a request to endorse EB-101.
Read →